GRANTS & Funding
This page contains links to information on TRI grant schemes and previous grant recipients. You can also click here to view links and ideas for external funding sources and bodies.
PARF/TRI COLLABORATIVE MICROGRANTS
The PARF/TRI Collaborative Microgrant provides seed funding of up to $3,000 to drive new, short-term research projects between Princess Alexandra Hospital-based clinicians (novice, early or mid-career) and TRI-based researchers. The funding will enable the clinicians to buy consumables or access services needed for the projects. Successful projects will be those demonstrating great potential in improving the lives of patients at the PAH. Your application also provides an opportunity to showcase your work, ideas and collaborations to PARF and its network of donors and supporters. FIND OUT MORE
Microba Lifesciences Microbiome sequencing grant
Microba Life Sciences is funding one grant of up to $13,250 to initiate and/or support microbiome-based research with translational applications. This grant is open to TRI-based researchers. TRI affiliated clinicians may also apply, ideally as a collaborative application with an emphasis on translation. FIND OUT MORE
Linc Grant Scheme
TRI, Metro South Health, Mater and Children's Health Queensland offer the jointly funded annual LINC grants, worth up to $50,000 each. These grants are aimed at fostering new collaborative research projects between TRI-based researchers and Metro South Health , Mater or Children's Health Queensland clinicians. FIND OUT MORE
TRI Research funding support - Requesting a Letter of support from TRI for Funding
- What is novel about the proposal and what is its value-add as a TRI investment for the TRI community.
- Previous funding requests to TRI (successful or not) to the same or a different funding body.
- How the application meets each of the criteria against which it will be assessed by TRI.
- Support from the Institute Director at TRI of the primary applicant (CIA).
TRI Foundation research grants
In 2022, the TRI Foundation offered two grant schemes in breast cancer and kidney disease research. Both grant schemes are for early to mid-career TRI-based researchers and affiliated clinicians. READ MORE
TRI-CSIRO Grant Scheme
In 2022, TRI and the CSIRO Australian e-Health Research Centre offered three $100,000 grants for collaborative research projects aimed at solving a healthcare challenge. All grant applications had to involve a TRI-based researcher, CSIRO Australian e-Health Research Centre scientist and a TRI partner clinician (from either Metro South Health, Mater or Children's Health Queensland). FIND OUT MORE
past TRI Grant Recipients
Prior to the LINC program, TRI ran the Spore and Drive grant schemes for translational research projects based at the Institute. The aim was to support researchers progress their discoveries and translate their findings into the clinic. Through Spore and Drive, TRI awarded $850,000 via 13 grants, with TRI’s partner institutions and industry collaborators matched this funding with a further $1,571,745.
|
Year awarded |
Grant scheme |
Principal Investigator |
Project title |
|
2022 |
LINC |
Dr Philip Rowell |
A bioengineered precision oncology platform for bone metastasis treatment. |
|
2022 |
LINC |
Dr Catherine Berman |
Clinical utility of [68Ga] FAPI PET/CT in patients with potentially resectable pancreatic cancer. |
|
2022 |
LINC |
Dr Kyle White |
Longitudinal profiling of TLR4 endocytosis and cellular reactivation in a Gram-negative sepsis cohort. |
|
2022 |
LINC |
Dr Markian Choptiany |
Improving tuberculosis diagnosis and care through functional immune screening. |
|
2022 |
LINC |
Dr Tirsa van Wyngaard |
Predictors of endocrine therapy response in luminal breast cancer: International collaborative research. |
|
2022 |
LINC |
Dr Taylan Gurgenci |
Medicinal cannabis, inflammation, and symptoms in advanced cancer (Cann-Inflam). |
|
2022 |
LINC |
Dr Shampavi Sri Haran |
Combating chemo-resistance amongst MYC amplified patients with neuroblastoma and medulloblastoma by inhibiting BRD4-MYC signalling axis. |
|
2022 |
TRI-CSIRO |
Prof Elizabeth Powell |
Utility of clinically relevant biomarkers to identify people with non-alcoholic fatty liver disease at increased risk of liver disease progression. |
|
2022 |
TRI-CSIRO |
Prof Erik Thompson |
Three-dimensionalising portable NMR assessment of mammographic density for improved breast cancer outcomes. |
|
2022 |
TRI-CSIRO |
Eamonn McKenna |
Feasibility of a smart footprint system for diabetes-related foot care |
|
2021 |
LINC |
Dr Justine Gibson |
Dysbiosis as a long-term sequelae in patients that undergo treatment for tuberculosis |
|
2021 |
LINC |
Dr Sidharth Mantha |
Establishing a pipeline for rapid clinical translation of novel biomaterials for the treatment of brain cancer of metastatic origin |
|
2021 |
LINC |
A/Prof Erin McMeniman |
Determining Causative Mechanisms of Hidradenitis Suppurativa |
|
2021 |
LINC |
Dr Philip Rowell |
Elucidating the Role of Adipokine Axis Dysregulation in Bone Metastatic Cancer for the Strategic Positioning of New Therapeutic Agents |
|
2021 |
LINC |
Dr Timothy Edwards |
Making treatment-resistant schizophrenia more treatable: predicting life-threatening clozapine-induced-neutropenia using cellular genomics. |
|
2021 |
LINC |
Dr Yoon-Kyo An |
Identifying mechanism and new therapies to treat anaemia of inflammation in Inflammatory Bowel Diseases |
|
2021 |
LINC |
Dr Reuben Beer |
Linking Advanced Neuroimaging, Disease State and Clinical Measures in Multiple Sclerosis: A multi-disciplinary and multi-institutional research approach. |
|
2021 |
LINC |
Dr Jesrine Hong |
DNA methylation in circulating free fetal DNA: A potential biomarker to predict fetal growth restriction and severe perinatal outcomes? |
|
2019 |
Spore |
A/Prof Jyotsna Batra |
Improving the PSA test to detect all lethal prostate cancers |
|
2019 |
Spore |
Prof Ben Panizza |
Therapeutic Potential for the Treatment of Adenoid Cystic Carcinoma (ACC) |
|
2019 |
Drive |
Prof Sandro Porceddu |
Durvax Trial: A Phase 1b, single centre, open label study of a therapeutic Human Papilomavirus (HPC) DNA vaccine co-administered with anti-PD-L1 immunotheraphy, Duravalumab (MED14736), for recurrent and/or metastatic HPV-related oropharnygeal cancer |
|
2018 |
Spore |
Prof Gerald Holtmann |
Modulation of the GI Microbiome with probiotics to treat constipation |
|
2018 |
Spore |
Prof John Hooper |
Theranostic biomolecules for improved diagnosis and treatment of pancreatic cancer |
|
2018 |
Spore |
Dr Arutha Kulasinghe |
Can liquid biopsy provide predictive biomarkers for checkpoint inhibitor response in Non-Small Cell Lung Cancer? |
|
2018 |
Spore |
Prof Peter Soyer |
Towards clinical diagnosis of inflammatory skin rashes using minimally‐invasive micro-sampling technologies |
|
2016 |
Spore |
A/Prof Jyotsna Batra |
Novel MicroRNA’s as potential targets for treating prostate cancer |
|
2016 |
Spore |
A/Prof Chamindie Punyadeera |
Circulating Tumour Cells as Biomarkers to Identify Head and Neck Cancer Patients for PD1 Therapy |
|
2015 |
Spore |
Dr Michelle Hill |
Obesity-induced Barrett’s oesophagus and associated cancer: mechanisms and diagnostic tools |
|
2015 |
Spore |
Dr Antje Blumenthal |
Towards biomarkers for patient stratification in sepsis |
|
2015 |
Spore |
Prof Rik Thompson |
Portable, single-sided MRI for routine, low-cost analysis of mammographic density |
|
2015 |
Spore |
Prof Ken O'Byrne |
Nucleoplasmin (NPM)1 a critical repair protein required for genomic stability |
